Small-cell lung carcinoma (SCLC) is a common form of lung cancer in which the tumor cells express neuroendocrine-like properties. SCLC is frequently associated with paraneoplastic disorders affecting the nervous system. Of particular interest is the Lambert-Eaton myasthenic syndrome (LES), an autoimmune disease of neuromuscular transmission that is often associated with SCLC (Lang et al., 1983; Kim, 1986; Vincent et al., 1989) . The target of the autoimmune reaction is thought to be a voltage-gated calcium channel in the presynaptic membrane that couples neurotransmitter release to membrane depolarization (Kim and Neher, 1988; Peers et al., 1990) . Autoantibody production may be triggered by the expression of a voltage-gated calcium channel in SCLC cells that resembles that found at the presynaptic nerve terminal (Roberts et al., 1985) .
Voltage-gated calcium channels (VGCCs) regulate calcium influx into neuronal cells and control the calcium-dependent release of neurotransmitters and peptide hormones (Miller, 1987) . It is likely that VGCCs play a similar role in SCLC cells, which are known to secrete a large number of ectopic hormones (Russell et al., 1990) . VGCCs are generally classified as L-, N-, P-, and T-type based on their electrophysiological behavior and distinct pharmacological sensitivities. Although P-type channels were originally described in Purkinje cells hence the name, there is now evidence for a wider distribution in the nervous system (Llinas et al., 1989; Hillman et al., 199 1; Regan et al., 199 1; Usowicz et al., 1992) . P-type channels are resistant to both dihydropyridine (DHP) antagonists and w-conotoxin GVIA (w-CgTx-GVIA), but are blocked by toxins isolated from venom of the funnel web spider. These toxins include a small polyamine toxin, funnel toxin @TX) (Llinls et al., 1989 (Llinls et al., , 1992 ) and a peptide toxin, w-agatoxin IVA (w-Aga-IVA) (Mintz et al., 1992a,b) . The release of the neurotransmitter glutamate at mammalian presynaptic nerve terminals is blocked by w-Aga-IVA, implicating P-type channels (Turner et al., 1992) . Furthermore, the mammalian neuromuscular junction contains P-type channels as indicated by the inhibition of presynaptic calcium flux by FTX (Uchitel et al., 1992) . The evoked release of acetylcholine at the mammalian neuromuscular junction is likewise blocked by FTX (Uchitel et al., 1992) and w-Aga-IVA . Finally, P-type channels are sensitive to a novel conotoxin, w-CgTx-MVIIC, that acts on mammalian presynaptic nerve terminals (Hillyard et al., 1992) .
The 01, subunit of VGCCs forms the pore of the channel and is evolutionarily related to voltage-gated Na+ and K+ channels. Six classes of calcium channel cyI subunits have now been identified by molecular cloning (Snutch and Reiner, 1992) . Three of these classes are believed to be L-type channels, including those isolated from skeletal and cardiac muscle and brain (Tanabe et al., 1987; Mikami et al., 1989; Hui et al., 1991) . A fourth class includes a presumptive P-type o(, subunit, called B 1, which was isolated from rabbit brain and expressed in Xenopus oocytes (Mori et al., 199 1) . It resembles P-type channels in its apparent tissue distribution; however, its single-channel properties and pharmacology are not entirely consistent with that of P-type channels described in Purkinje cells (Sather et al., 1993) . A fifth class of a, subunits is sensitive to w-CgTx-GVIA and therefore corresponds to N-type channels (Dubel et al., 1992; Williams et al., 1992) . Finally, the most recently described class has characteristics of a low-voltage-activated (T-type) calcium channel (Soong et al., 1993) . The functional properties of another recently cloned calcium channel have not yet been described (Niidome et al., 1992) , but the channel appears to be most closely related to a calcium channel isolated from a marine ray that expresses novel kinetic and pharmacological characteristics (Elliner et al., 1993) .
There is considerable evidence that SCLC cells express voltage-gated calcium channels. Depolarization-induced Ca2+ flux in SCLC cells is inhibited by DHP antagonists and w-CgTx-GVIA, thereby suggesting the presence of L-and N-type channels (De Aizpurua et al., 1988; Sher et al., 1990) . In addition, the whole-cell patch-clamp technique has been used to demonstrate the presence of DHP-sensitive L-type channels (Pancrazio et al., 1989; Pancrazio et al., 1992) . In the present study we identify a presumptive P-type VGCC transcript in SCLC cells. A polyclonal antiserum was produced to a peptide encoded by a partial cDNA clone. The purified antibodies inhibited calcium currents expressed in SCLC cells, as did the P-type channel-specific toxin w-Aga-IVA. These results provide evidence for the expression of a P-type calcium channel in SCLC cells.
Materials and Methods
Cell culture H 146, H209, and H345 human small-cell lung carcinoma cells (Gazdar et al., 1980) were obtained from American Type Culture Collection and cultured in RPM1 1640 medium (GIBCO/Bethesda Research Labs) supplemented with 10% fetal bovine serum (GIBCO/Bethesda Research Labs). H146 cells were chosen as the experimental model due to their robust calcium currents (Pancrazio et al., 1989) ; normal untreated H146 cells demonstrate maximal Ic, ranging from 10 pA to 375 pA [mean of 115.8 f 3.9 (?SEM) pA, n = 303 cells]. The C2 mouse muscle cell line was cultured as described (Silberstein et al., 1982) and fused myotubes were used for the isolation of RNA.
Isolation of cDNA clones by PCR Purification of RNA. PolyA+ RNA was isolated from cultured cells as previously described (Bradley et al., 1988) . Briefly, cells were pelleted bv centrifuzation and homogenized in the presence of 2% SDS. After incubation-with proteinase K (Boehringer Mannheim), the cell lysate was batch adsorbed to oligo(dT) cellulose (Collaborative Research), and polyA+ RNA was eluted in salt-free buffer.
First-strand cDNA synthesis. PolyA+ RNA, 10 pg, was reverse transcribed in a 100 ~1 reaction volume containing 10 U/PI Moloney murine leukemia viral reverse transcriptase (GIBCO/Bethesda Research Labs), 10 ng/pl random hexamers (Pharmacia), 0.5 mM dNTPs (Pharmacia), 100 rg/ml bovine serum albumin (GIBCO/Bethesda Research Labs), and 1 U/w1 RNasin (Promega) in 50 mM Tris-HCl, pH 8.3,75 mM KCl, 10 mM dithiothreitol (DTT), and 3 mM MgCl,. The mixture was incubated for 5 min at room temperature (to extend the hexamers) followed by 1 hr at 37°C. The cDNA product was isolated by phenol: chloroform extraction and ethanol precipitation for use in PCR.
PCR. Aliquots of cDNA, equivalent to l/l0 of the above reaction, were incubated in a 100 r.d reaction volume containing 10 mM TrisHCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl,, 0.001% gelatin, 200 PM of each dNTP, 0.2 PM of each primer, and 2.5 U of DNA polymerase (amplitaq, Perkin-Elmer), and overlaid with 100 pl of mineral oil (Sigma). PCR was performed on an automated thermalcycler (Perkin-Elmer Cetus) that was programmed to repeat the following cycle 30 times: 60 set at 94"C, 60 set at 60°C and then 120 + 2 set/cycle at 72°C. PCR primers. Primers were designed from regions that are perfectly conserved between rabbit skeletal (Tanabe et al., 1987) and cardiac muscle (Mikami et al., 1989 ) L-type calcium channels. The sequence of the upstream primer was 5'-gtgggaattcatcaagtccttccaggccct-3', and the downstream primer, 5'-caggggatccaagttgtccatgatgacagc-3'. Restriction sites (italic) were included near the 5' ends of the primers to facilitate directional subcloning: EcoRl in the upstream primer and BamHl in the downstream primer. The PCR primers were synthesized locally and crude trityl-on oligonucleotides were eluted from the glass support columns with ammonium hydroxide and purified on Nensorb (DuPont) prep columns.
Cloning. The products of the PCR reaction were directionally cloned into the Bluescript KS vector (Stratagene). Initially, one-fifth of each PCR reaction was analyzed by electrophoresis on 3% Nuseive/ 1% Seakem agarose (FMC) gels. For subcloning, the remaining reaction product was purified by phenol extraction and ethanol precipitation, digested with EcoRl and BamH 1, and isolated as a band from a low-melt Nuseive/agarose gel. The vector was also digested with EcoR 1 and BamH 1 and isolated on a low-melt agarose gel. The PCR product and vector were ligated and used to transform XL-1 Blue bacteria. Plasmid DNA was prepared from individual colonies and sequenced by the dideoxynucleotide chain termination procedure from double-stranded DNA templates. Sequence comparison was performed using the Intelligenetics and the Genetics Computer Group on-line software.
Northern blot analysis
Total RNA was isolated from cultured cells by the guanidinium isothiocyanate/phenol procedure (Chomczynski and Sacchi, 1987) . Total RNA, 50 pg, was run in each lane of an 0.8% agarose-formaldehyde denaturing gel and electrophoretically transferred to Genescreen nylon membrane (DuPont). The membranes were UV cross-linked and then prehybridized in 0.75 M NaCl, 0.05 M NaH,PO,, 5 mM EDTA, 0.1% Ficoll, 0.1% polyvinylpyrrolidone, 0.1% bovine serum albumin (BSA) (Pentax Fraction V), 50% formamide, 1% SDS, 10% dextran sulfate, and 100 pg/ml salmon sperm DNA at 45°C for 20 hr. Hybridization with '*P-labeled riboprobes was carried out under the same conditions as the prehybridization. The membranes were then washed in 15 mM NaCl. 1 mM NaH,PO,. 0.1 mM EDTA. and 0.1% SDS at 65°C and treated with 1 &ml RNase A for 15 min in 0.3 M NaCl and 30 mM Na,citrate to decrease background interference. Autoradiography was carried out at -70°C with an intensifying screen. Hybridization with a control riboprobe for human p-actin was used to demonstrate that similar amounts of undegraded RNA were probed in each lane (not shown).
Production and characterization of polyclonal antibodies
Peptide design and antibody isolation. A peptide, NH,-IDVEDEDS-DEDEFC-CO,, corresponding to a unique nucleotide stretch (residues 79-l 18) in clone SCLC-P, was synthesized, conjugated to keyhole limpet hemocyanin, and used for the production of antiserum in rabbits (Macromolecular Resources, Fort Collins, CO). Peptide-specific antibody was purified by affinity chromatography. Peptide, 25 mg, was solubilized in DMSO and coupled to 2 ml of Affi Gel-10 resin (Bio-Rad). Antiserum was heat inactivated and batch absorbed to peptide resin equilibrated in 137 mM NaCI, 2.7 mM KCl, 4.3 mM Na,HPO,, and 1.4 mM KH,PO, (PBS). Antibody was eluted in 0.2 M glycine, pH 2.5, immediately neutralized with 1.5 M Tris, pH 8.8, and dialyzed against PBS. The affinitypurified antibody was used for Western blotting and immunofluorescence and in patch-clamp experiments.
Subcloning the SCLC-P clone into a bacterial expression vector. The SCLC-P clone was subcloned into the BamH 1 site of the bacterial expression vector pGEX-3X (Pharmacia) as follows. SCLC-P cDNA generated by PCR was restriction digested at the 3' end with Mbol at nucleotide 17, generating sticky ends that are compatible with those generated by BamH 1, and at the 5' end with BamH 1 at the site engineered into the PCR primer. The restricted SCLC-P DNA was ligated to the BamH 1 -digested vector and the products were used to transform XL-I Blue bacteria. Recombinants containing the SCLC-P insert in the sense orientation were selected by restriction analysis and used for the expression of a fusion protein.
Expression of the SCLC-P fusion protein. Transformed bacteria containing either the SCLC-P recombinant vector or control vector (without insert) were grown overnight at 37°C in LB medium containing ampicillin. Cultures were diluted 1: 10 in fresh medium and grown for 1 hr before expression of the glutathione-S-transferase (GST) fusion protein was induced by the addition of IPTG, 0.1 mM final concentration. After 5 hr, the cells were harvested by centrifugation and solubilized in gel sample buffer (0.125 M Tris-HCl, pH 7.4, 4% SDS, 200 mM DTT, 20% glycerol, bromphenol blue). Total-cell lysates were analyzed by electronhoresis on 12% SDS-PAGE gels. Some lanes of the ael were cut out for visualization of protein by-staining with Coomassye brilliant blue. Duplicate lanes from the gel were electrophoretically transferred to nitrocellulose paper for Western blotting.
Western blotting. Duplicate nitrocellulose strips were incubated in 10 mM Tris-HCl, pH 7.4,500 mM NaCI, 0.05% Tween-20,0.1% cold water fish gelatin, 0.08% BSA, and 6% normal goat serum at room temperature Figure 1 . Sequence of SCLC-P Ca2+ channel 01~ subunit cDNA clone. The nucleotide sequence (4) and the deduced amino acid sequence (B) of the SCLC-P clone (ZZumSCLC-P) are compared with the rabbit brain (P-type) Caz+ channel sequence (RubBrain-P) (Mori et al., 1991) . Residues that are identical are connected by dashes. The numbers at ends of each line are the nucleotide or amino acid residue numbers. The putative transmembrane segments (II'S5 and Zl'S6) of the fourth homology domain are indicated by lines above the sequence. A peptide corresponding to the underlined residues in the SCLC-P amino acid sequence (B) was used for the production of polyclonal antibodies. C, A comparison of the deduced amino acid sequences of six classes of Ca*+ channels with that of the SCLC-P clone in the vicinity of a unique acidic region. The sequences shown are the SCLC-P clone described in this manuscript (ZZumSCLC-P), the rabbit brain P-type Ca*+ channel (RubBruin-P) (Mori et al., 1991) , the human brain N-type Ca2+ channel (HumBrain-&') (Williams et al., 1992) , the rat brain T-type Caz+ channel (RatBrain-T) (Soong et al., 1993) , the rabbit skeletal muscle L-type Cal+ channel (RubSkeletal) (Tanabe et al., 1987 ) the rabbit cardiac muscle L-type Ca*+ channel (RabCardiac) (Mikami et al., 1989) and the rat brain L-type Ca 2+ channel (RatBrain-L) (Hui et al, , 199 1) .
as follows: (1) 1 hr without antibody to block nonspecific binding sites, (2) 8 hr with 5 nM affinity-purified anti-peptide antibody, and (3) 1 hr with alkaline phosphatase-conjugated goat anti-rabbit secondary antibody (1: 10,000) (Jackson Immunoresearch). The strips were developed using 5-bromo-4-chloro-3-indolyl phosphate and nitro blue tetrazolium (Sigma). In some cases the anti-peptide antibody used in step 2 was preincubated for 1 hr with 26 PM peptide to determine nonspecific binding. Zmmunofluorescence. Immunofluorescence was performed on cells in suspension at room temperature. The cells were pelleted at 6000 rpm for 1 min and the supematant was aspirated for solution changes. Cells were washed three times in PBS and fixed in 1% paraformaldehyde containing 150 mM lysine for 30 min. All subsequent incubations and washes were in PBS, 0.1% cold water fish gelatin, 0.08% BSA, and 6% normal goat serum. Cells were incubation for 30 min in the absence of antibody and then for 70 min with 100 nM affinity-purified anti-peptide antibody. In some cases the anti-peptide antibody was preincubated for 1 hr with 26 I.LM peptide to determine nonspecific binding. The cells were washed three times and incubated with fluorescein-conjugatedgoat anti-rabbit secondary antibody (1:200) (Jackson Immunoresearch) for 50 min. After three additional washes, the cells were pelleted, resuspended in 30% glycerol, 12% Mowiol (Calbiochem), 120 mM Tris, pH 8.5, and mounted on glass slides. Photographs were taken on a Zeiss microscope using a 63 x oil-immersion objective.
Incubation of HI46 cells with antibodies
Prior to applying the antibodies to the H 146 cells, both control (rabbit IgG, Sigma) and anti-peptide antibodies were dialyzed against RPM1 for 48 hr with one dialysate change at 24 hr. Antibodies were then diluted into the cancer cell suspension to the desired concentration (0.02 or 0.04 mg/ml IgG) and allowed to react with the cells for 1 hr at 37°C. To affix the cells for patch-clamp recordings, the cell suspension was plated onto poly-L-lysine-coated (Sigma) coverslips and returned to 37°C for 1 hr. Thus, the cells were exposed to the antibodies for a total of 2 hr prior to patch-clamp analysis. Experiments were carried out using cells that had been subcultured the previous day. For a given experiment, control and treatment cells were always taken from the same culture flask.
Patch-clamp recordings
Standard patch-clamp protocols were used to obtain whole-cell recordings of Z,, and Zc, (Hamill et al., 1981) . Patch-clamp pipettes were fashioned from borosilicate glass (Kimax-1, Kimble Products, Vineland, NJ) and the tips coated with Sylgard (Dow Coming, Midland, MI) to reduce pipette capacitance. Pipettes typically had resistances of -2 MR. Prior to eliciting voltage protocols, cells were maintained at the holding potential for 1 min. Voltage clamping was performed with an L/M-EPC-7 patch-clamp amplifier (List Medical, Darmstadt, Germany). Signals were filtered through an b-pole low-pass Bessel filter (Frequency Devices, Haverhill, MA) with a cutoff frequency of 3 kHz. Data acquisition and analysis were accomplished with FRUMP software (Axon Instruments, Foster City, CA) using a PC-compatible 486 computer and Lab Master DMA TL-1 interface (Axon Instruments). From the holding potential, 7-16 consecutive depolarizations ranging from -60 mV to +90 mV in 10 mV increments were applied to each cell. Pulses were of 350 msec duration at a frequency of 0.2 Hz and sampled at 2.5 kHz. A P/4 procedure (Armstrong and Bezanilla, 1977 ) was used to eliminate capacitative and leak currents. For all recordings, the patch-clamp pipettes were filled with 120 mM CsCl, 20 mM TEA-Cl, 11 mM EGTA-NaOH, 1 mM CaCl,, 2 mM MgCl,, and 10 mM HEPES-NaOH, pH 7.2. The external recording solution consisted of 130 mM NaCl, 5 mM KCl, 10 mM CaCl,, and 10 mM HEPES-NaOH. oH 7.2. For all exneriments in which the cells were exposed to w&A-IVA, 10 mM BaCl, was substituted for the CaCl, in the bath solution. w-CgTx-GVIA (Sigma) and w-Aga-IVA were stored frozen at -20°C as stocks after reconstitution. Stock solutions were diluted into the recording chamber to achieve the desired final concentration of drug (bath volumes were 1 or 2 ml). Nifedipine (Sigma) was dissolved in DMSO and stored at 4°C. Before each experiment, the nifedinine stock was diluted to working stocks with distilled H,O. All nifedipine experiments were performed% a darkened environment. To avoid time-dependent effects, cells were pretreated for 10 min with vehicle or drug and recordings were made 1 min after establishment of a whole-cell patch.
2.4-
I,, was taken as the peak transient component occurring within the first 5 msec. Peak Zc, was measured as the maximum current between 18 and 60 msec from the start of the depolarization. Plateau Zc= was , .
are indicated (in kilodaltons). Duplicate lanes were transferred to nitrocellulose strips for blotting with an anti-peptide antibody in the absence (middle) or presence (rzght) of competing peptide. measured as the current at the end of the 350 msec pulse. To avoid discrepancies due to cell size, current valtres for each cell were divided by the capacitance of that cell and currents were reported as current density (pA/pF). Experiments were done in pairs; each data set was normalized against its own control and results were pooled across experiments to obtain mean f SEM. Student's t test was used for statistical analyses; p < 0.05 was considered significant.
Results
Isolation and characterization of SCLC calcium channel cDNA clones Partial cDNA clones corresponding to putative Ca2+ channel 01, subunits were isolated from human H 146 SCLC cells using the polymerase chain reaction (PCR). The sequences of the SCLC clones obtained were compared to the published sequences of Caz+ channels. One of these clones, SCLC-P (345 bp), is most highly homologous to the presumptive P-type Caz+ channels isolated from rabbit (called B 1; Mori et al., 199 1) and rat brain (called rbA; Starr et al., 199 1) . The degree of homology to the Bl transcript is 89.7% at the nucleotidelevel (Fig. 1A) and 98.2% at the amino acid level (Fig. lB) , whereas homology to the skeletal muscle L-type channel (Tanabe et al., 1987 ) is 63.1% and 54.7%, respectively (not shown). The high degree of homology suggests that this clone represents the human homolog of the rabbit brain channel described by Mori et al., and not a novel form of calcium channel. This clone contains a small region of particular interest: a short stretch (24 nucleotides) coding for very acidic amino acids that appears to be unique to this type of calcium channel (Fig. 1 C) . This acidic region is not found in any of the three classes of L-type channels (Tanabe et al., 1987; Mikami et al., 1989; Hui et al., 1991; Snutch et al., 1991) or in the presumptive N-type channels that have been described to date (Dubel et al., 1992; Williams et al., 1992) , nor is this sequence found in a member of the low-voltage-activated (T-type) calcium channel family recently cloned from rat brain (Soong et al., 1993) . It is also not present in a novel channel from rabbit brain (Niidome et al., 1992) (not shown).
Northern analysis was used to detect expression of mRNA transcripts corresponding to the SCLC-P clone (Fig. 2) . The SCLC-P clone hybridized to a single mRNA of approximately 9.0 kb from the H146 SCLC cell line (lane 1) but not to any mRNA isolated from a muscle cell line (lane 2) that was used as a negative control. An L-type calcium channel probe detected a 6.5 kb band in muscle RNA, thereby demonstrating the integrity of the RNA (not shown). The 9.0 kb message in SCLC is approximately the same size as that reported for the Bl calcium channel transcript in rabbit brain (Mori et al., 1991) . To determine if expression of this Ca*+ channel mRNA is common to other SCLC cell lines, total RNA was prepared from H345 and H209 cells. Clone SCLC-P hybridized to a single 9.0 kb mRNA from these cells as well (not shown).
Production and characterization of polyclonal anti-peptide antibodies As described above, we have found evidence for the presence of the transcript for a presumptive P-type calcium channel in human SCLC cells. To study the expression of the calcium channel protein, antibodies were raised to a unique acidic peptide, IDVEDEDSDEDEF, corresponding to a cDNA sequence in the IV S5-S6 linker region of SCLC-P (Fig. 1B) . This peptide has not been found in any of the other classes of calcium channels cloned to date (Fig. 1C) and is predicted to be located on the extracellular side of the membrane.
To determine the specificity of the antibodies, they were used for western blotting of the SCLC-P clone expressed as a fusion protein with GST (glutathione-S-transferase). Total cell lysates 'from bacterial cell cultures were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (Fig. 3) . The 27,500 Da GST protein was the major band seen in lysates from cells transformed with control vector (no SCLC-P insert) and induced with IPTG (Fig. 3, left, lane 1) . When cells were transformed with recombinant vector containing the SCLC-P clone insert, a major inducible protein band of approximately 40,000 Da was seen, which corresponds to the predicted size of the fusion protein (Fig. 3, left, lane 2) . Western blot analysis revealed that the antibody bound to the 40,000 Da SCLC-P-GST fusion protein band from recombinant cell lysates (Fig. 3 , middle, lane 2). Some smaller bands were also seen that are believed to be degradation products of the fusion protein. However, the antibody did not bind to any of the proteins in the control cellular lysate (Fig. 3, middle, lane 1) . In addition, binding to the fusion protein was inhibited by preincubation of antibody with peptide (Fig. 3, right, lane 2) . Thus, the anti-peptide antibody bound specifically to the SCLC-P portion of the fusion protein.
We were unable to detect the SCLC calcium channel protein, or any other protein, by immunoblotting total cell lysates from H 146 cells. This result is not surprising because the channel is likely to make up too small a portion of the total cellular protein to be detected by this method. Therefore, at least partial purification ofthe protein may be necessary before it can be detected.
Immunofluorescence was performed on nonpermeabilized SCLC cells to determine if the anti-peptide antibody recognized a native molecule on the cell surface. Antibody bound to the surface of H 146 cells (Fig. 4~) . Binding was inhibited by preincubation of antibody with peptide (Fig. 4b) . Similar results were obtained with the H345 and H209 SCLC cell lines (not shown). Very low background levels of binding of control rabbit IgG were detected, but binding was not blocked by preincubation with peptide (not shown). These results indicate that the antipeptide antibody recognizes a protein that is expressed on the surface of SCLC cells and are consistent with the proposed localization of the antigen (VGCC) to the cell membrane.
Inhibition of calcium currents by anti-peptide antibodies
The anti-peptide antibodies are predicted to bind near the extracellular entrance to the pore of the calcium channel; thus, it is possible that binding may inhibit channel activity. Inhibition ofcalcium currents in H 146 cells was examined using the wholecell patch-clamp technique. Inward currents from H146 cells were elicited at a range of potentials from a holding potential of -80 mV. In cells exposed to 10 mM [Ca2+],, the whole-cell currents were characterized by an initial transient component consisting of current carried by sodium (INa) and a second longlasting component, the calcium current (I,,) (see Figs. 54, 6A ). H 146 cells were treated with control or anti-peptide antibodies (0.02 mg/ml IgG) for 2 hr prior to patch-clamp analysis. Both peak I,, (measured at the beginning of the depolarization) and plateau Z,, (measured at the end of the 350 msec depolarization) were studied because other reports suggest that P-type channels do not inactivate with long depolarization (Llinas et al., 1989; Regan et al., 199 1; Usowicz et al., 1992) . Peak Zc,, which was maximal at + 10 mV, was reduced by 20 -t 6% (mean t SEM, y2 = 25 cells, p < 0.05) in cells treated with anti-peptide antibodies relative to cells treated with control antibodies (Fig. 5) . The anti-peptide antibodies did not inhibit peak Zc= evoked at potentials below + 10 mV, although peak I,, measured from + 10 mV to + 30 mV was similarly reduced by approximately 20%. The plateau I,, measured during depolarization to + 10 mV was likewise diminished by 19 ? 7% (n = 25 cells, p < 0.05) after exposure to the anti-peptide antibodies (Fig. 5C ).
Increasing the concentration of antibody to 0.04 mg/ml did not increase the amount of reduction observed; therefore, a concentration of 0.02 mg/ml IgG was used for all subsequent experiments.
To confirm that the antibodies reduce I,, by specifically inhibiting the action of calcium channels, we assessed antibody effects on ZNa in the same cells used for I,, analyses. Accordingly, cells that had been incubated in the anti-peptide antibodies exhibited a maximal Z,, of 54.3 * 5.5 pA/pF (n = 25), which was not significantly different from the control Z,, of 6 1.4 f 5.1 pA/pF (n = 33, p > 0.1) (not shown).
If the antibodies inhibit a P-type calcium channel in H146 cells, then it would be expected that (1) I,, should be sensitive to w-Aga-IVA, (2) the inhibitory effect of the antibodies and the w-Aga-IVA on the Zc, should not be additive, and (3) the antibodies should reduce the I,, in the presence of a DHP antagonist and w-CgTx-GVIA. To test these hypotheses, we performed the following experiments.
To assess the effect of w-Aga-IVA on calcium channel activity, 10 mM BaCl, was substituted for the CaCl, in the bath solution. This permitted comparison with previous reports on the effects ofw-Aga-IVA (Regan et al., 1991; Mintz et al., 1992b) . Treatment of H146 cells with 50 nM w-Aga-IVA for 10 min reduced the magnitude of the peak I,, by 28 * 6% (n = 29 cells, p < 0.005) (Fig. 6) . Similarly, the plateau phase of the I,, was reduced by 26 + 7% (n = 29, p < 0.025) (Fig. 6C) . The shape of the current-voltage curves and the reversal potential were unchanged after incubation with toxin; only the magnitudes of the currents were reduced. In addition, ZNa was not significantly affected by the w-Aga-IVA (not shown).
The effect of w-Aga-IVA was also assessed on H 146 cells that were pretreated for 2 hr with anti-peptide antibodies and subsequently exposed to 50 nM w-Aga-IVA (Fig. 7) . Peak Zc, was reduced by 32 f 8% (n = 18 cells, p < 0.05); a reduction similar to that observed when the toxin was applied alone. Although it appears that the toxin and antibody combination may inhibit I,, slightly more than either agent alone, the difference is not statistically significant. These results support the hypothesis that the antibody and the toxin act on the same type of calcium channel in H146 cells.
H146 cells are known to express I,, that is sensitive to both DHP antagonists and w-CgTx-GVIA . P-type calcium channels, however, are insensitive to these agents (Mintz et al., 1992b) . Therefore, we examined whether the antibodies were effective at reducing the I,, that remained after their application. In the absence of antibody, 10 NM nifedipine and 1 FM w-CgTx-GVIA inhibit 40 + 6% of peak I,, and 47 -t 6% of plateau I,, (Fig. 7) . With these additional agents in the recording solution, the anti-peptide antibodies reduced the peak and plateau Z,., by 66 k 10% (n = 16 cells) and 85 * 9% (n = 16 cells), respectively (Fig. 7) . Notably, in the presence of nifedipine and w-CgTx-GVIA, the plateau I,, (where the nifedipine is most effective) was reduced to a greater extent than the peak Ic,. The anti-peptide antibodies and the w-Aga-IVA, on the other hand, were equally effective as inhibitors of peak and plateau IcB (see Figs. 5, 6) . When these experiments were carried out from a holding potential of -40 mV instead of -80 mV, the antibodies were similarly effective, inhibiting the peak Z,, by 70 + 9% (n = 16 cells) and the plateau Zc. by 78 + 8% (n = 16 cells) (not shown). This observation agrees with published reports that P-type channels are functional with a more depolarized holding potential (Regan et al., 199 1) . In conclusion, these results demonstrate that the anti-peptide antibodies act on a component of the current that remains after application of nifedipine and w-CgTx-GVIA.
Discussion
In the present study we describe the presence of a P-type VGCC 01, subunit in SCLC cells. We have isolated from human H146 SCLC cells a partial cDNA clone (SCLC-P) that is highly homologous to putative P-type VGCC (Y, subunits cloned from rabbit (Mori et al., 199 1) and rat (Starr et al., 199 1) brain. Antibodies raised to a unique acidic peptide encoded by this cDNA clone inhibited calcium current induced by depolarizing potentials in SCLC cells. Current models of VGCC membrane topology suggest that relatively little of the (Y, subunit is exposed on the extracellular surface ofthe membrane. The acidic peptide against which our antibodies were generated is predicted to be located near the extracellular entrance to the channel pore just upstream of the SS 1 and SS2 membrane-spanning domains (HS segment) that are thought to line the pore of the channel, as evidenced by mutational analysis of the corresponding regions in sodium and potassium channels (Yellen et al., 1991; Heinemann et al., 1992) and, more recently, in a calcium channel (Tang et al., 1993) . Our data support a model in which this region is exposed at the extracellular surface because the antipeptide antibodies bind extracellularly and interfere with calcium currents. We have also shown that the P-type-specific toxin w-Aga-IVA inhibits calcium currents in SCLC cells. It is worth noting that while the antibodies block approximately 20% of the calcium current, w-Aga-IVA blocks a larger percentage, approximately 28%. However, the mechanism of the inhibitory effect of the antibody is not known; it could result either from the obstruction of the open channel or by preventing the channel from achieving an open conformation. Thus, there is no reason to expect complete inhibition ofchannel activity by the antibody because, for example, it may only partially occlude the channel pore. It could be that the agatoxin provides a more complete block of channel function. Another possibility is that the antibody inhibits only a subclass of P-type channels while the toxin inhibits additional channels. Notably, the nonadditivity of the inhibitory effects of toxin and anti-peptide antibodies is consistent with their action on the same type of channel. While apparent differences in the functional properties of a putative P-type transcript (BI) expressed in Xenopus oocytes and P-type calcium channels characterized in native tissues have been described (Sather et al., 1993) these differences may be attributable to the expression system. Our results characterizing native expression in SCLC cells support the hypothesis that the SCLC-P transcript encodes a P-type channel.
Neither the anti-peptide antibodies nor the w-Aga-IVA cause a complete block of calcium currents because SCLC cells have multiple types of VGCCs. In addition to the SCLC-P clone described here, we have isolated partial cDNAs corresponding to the a!, subunit of L-type VGCCs from H 146 SCLC cells (Barry and Froehner, 199 1) . The presence of L-type VGCCs is consistent with the known inhibitory effects of DHP antagonists on calcium currents (Pancrazio et al., 1992) . Our anti-peptide antibodies inhibit a component of the calcium current that is not blocked by application of inhibitors of L-type and N-type calcium channels (nifedipine and w-CgTx-GVIA, respectively). This data demonstrates the specificity of the antibodies for P-type calcium channels. It is interesting that even in the presence of anti-peptide antibodies, nifedipine, and w-CgTx-GVIA, some calcium current remains in these cells. Similar resistant currents have been reported in neuronal cells (Mintz et al., 1992a) .
A presynaptic calcium channel that regulates cholinergic transmitter release from the mammalian motor nerve terminal is thought to be the target of autoantibodies in the neuromuscular disease LES, which is commonly associated with SCLC (Vincent et al., 1989 ). Although it is not known which type of VGCC is the relevant target for LES autoantibodies, several studies have provided evidence for binding of LES antibodies to either N-type or L-type VGCCs. LES IgG immunoprecipitates w-CgTx-GVIA receptor complexes implicating N-type channels (Sher et al., 1989 (Sher et al., , 1990 Leys et al., 199 1) . The results of patch-clamp experiments suggest inhibition of L-type VGCCs by LES antibodies (Peers et al., 1990) . However, the release of acetylcholine at the mammalian neuromuscular junction is not inhibited by w-CgTx-GVIA (Olivera et al., 1985; Sano et al., 1987; Du Luca et al., 199 1; Protti et al., 1991) or DHPs (Atchison, 1989; Burges and Wray, 1989) . On the other hand, the release ofacetylcholine is inhibited by FTX (Uchitel et al., 1992) and w-Aga-IVA implicating P-type channels in this process. Thus, the P-type calcium channel that we describe in SCLC cells may be a candidate for an SCLC antigen involved in the induction of LES. Evidence in our preliminary experiments demonstrating that LES IgG indeed downregulates the P-type calcium channel in SCLC cells is consistent with this proposal. It may now be possible to test the role of P-type channels in LES by injecting animals with either a fusion protein containing the SCLC-P clone or with the acidic peptide itself and examining the animals for the development of LES symptoms. Immunoreactivity of LES sera with two calcium channel-associated proteins, the P-subunit (Rosenfeld et al., 1993) and synaptotagmin (Leveque et al., 1992) , has been reported. Therefore, it is worth considering that LES autoantibodies may cross-react with several different types of VGCCs due to the presence of homologous epitopes on their LYE subunits or to the sharing of accessory subunits or other associated proteins.
